A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Pfizer
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jan 2012 Planned end date changed from 1 May 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.